In search of a potential (subclinical) immuno-inhibitory effect of IFNβ we here prospectively monitored humoral and cellular vaccine-specific immunity in a cohort of patients with MS defined by clinical and radiological response to IFNβ-treatment as well as in healthy controls. The gene discussed is IFNB1; the disease is myeloid sarcoma.